Biography
Peter is a medical oncologist and an oncology drug developer with 17 years of oncology drug development experience, 15 years in the industry. He currently oversees Late-Stage Oncology Development at DSI, and previously held the role of VP, Section Head of GU Oncology at Merck Inc. Over his tenure, Peter was responsible for the clinical development and approval of multiple important medicines, including Keytruda and Enhertu, for melanoma, MSI-H tumors, and a wide range of other cancers such as esophageal, gastric, pancreatic, renal cell, urothelial, prostate, breast, and lung cancers.